Jan. 07--Huntington Beach-based surfwear company Quiksilver is extending its brand name to a new action-sports hotel concept called Quiksilver Hotels & Resorts International. The exclusive licensing agreement encompasses use of Quiksilver's brand and retail presence, but QHRI is a separate entity from the publicly traded surf-apparel company.
Matteson Capital, the Newport Beach developers behind the QHRI project, began raising a first round of $250 million in November. Over the next three to five years, the money will be used to build and acquire a handful of properties that feature amenities like on-site concert venues, skate parks, surf pools and indoor skydiving, in partnership with big names like Kelly Slater and Tony Hawk.
"Quiksilver had a vision to extend its brand into hotels. It's designed to be a family-friendly, three- to four-star chain -- more a place where people can travel with families and have their kids be active," said Jay Rogers, president of Alpha Strategies Investment Marketing, the firm in charge of QHRI's marketing efforts. "The hotel development group is constantly looking at new properties and taking over existing brands, not only in Hawaii and Bali and Costa Rica, but inland areas as well, like Anaheim and Orlando next to Disney."
According to Rogers, the first property will likely open in Palm Springs, where QHRI is developing a 35-acre tract of land for a flagship resort.
WOW, does our new executive team have thoughts of their old Disney days?
Google article title if interested, "Surf Apparel Quiksilver on Board with Hotel Concept"
I know the MACB folks, lots of cash from that deal to get us where we need to be. I'm patient, parked and waiting for signs of life. How about some INSIDER buying. Show us the money LUNA executive team.
GLTA (Longs that is) :-)
Even BIGGER money, and actually why I'm here.
Todays news is ADDED gravy, and in fact, looks like with NBI-98854, we now have a pipeline in a product. Oh baby!!!!!!
GLTA (Longs that is) :-)
Price target raised to $22
If interested in complete article, Google title, "Ahead of the Bell: Neurocrine shares keep climbing"
GLTA ( Longs that is) :-)
If interested in complete article, Google title, "C-Pulse device designed to help patients with advanced heart failure"
Rosa says he is less concerned with possible competitors than with developing the market. He says his company hasn’t explored a merger, but it does have a large cardiovascular company – which he declined to identify –- as an investor.
“I think there are a number of companies that would like to get into this space, but it’s not as crowded as some other markets,” Rosa says. “There hasn’t been a successful technology in the class three heart failure space. With some of the clinical results that we’re getting, we’re pretty excited, and we think physicians are also going to be excited."
Sounds pretty weak. ;-(
WSJ article, 12/13/2013- "Lpath Inc. LPTN -0.93% said it is no longer actively seeking to reacquire exclusive rights to its leading product candidate from Pfizer Inc., PFE +0.33% saying the pharmaceutical giant informed the company that its offers weren't competitive.
The biotechnology company in October had warned that Pfizer may divest itself of its exclusive option to co-develop the smaller firm's leading product candidate—known as iSONEP.
"We made a serious effort to reacquire this asset, and we continue to believe in iSONEP's prospects," Lpath Chief Executive Scott Pancoast said. However, he also said the company isn't currently in a position to increase its offer. Further financial details weren't provided.
The company first entered into an agreement with Pfizer in late 2010, under which Pfizer obtained an exclusive option for the world-wide license to develop and commercialize the treatment for the eye condition wet age-related macular degeneration.
Terms of the original agreement with Pfizer included a $14 million upfront payment and shared cost of the Phase 2 clinical trial. Additionally, if Pfizer opted in after more data was obtained, future payments could be received by Lpath"
$50 mill market cap. Len could buy them with the lint in his pocket.
Nope, and AGREE compleetly. 1 BILLION dollar valuationt for Mandiant and less that &500 mill for us. KEYW to go much high. PLUS, we have THE PLANES, THE PLANES, LOL :-)
REGN had its issues/setbacks, BDNF for ALS, and a weight loss drug., etc but we had driven and committed founders, intent on succeeding, REMOVING obstacles, and not giving up. Lenny went after and got Dr. Vagelos on the board, was he the difference, I would argue it was their determination not to fail, in combination with Dr. V. If interested, you can Google and read an article titled, "How Two Guys From Queens Are Changing Drug Discovery" and it will give you more background. Do we have that determination in our team at IMGN? Personally, I believe so, given what they have accomplished and how long they have been striving. It's certainly not a simple thing to win at this game, and did they or the REGN team take the most efficient path to success, probably not, but given imperfect information, my hope/belief is our team at IMGN is as determined to win/succeed, in a VERY HARD game. I believe one day will wake up and IMGN will be an over night success as well.